SCHEMBL6035480

SCHEMBL6035480

COC(=O)Cc1ccc(OC)cc1O

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.64
ALDH1A1 P00352 2/20 0.54
HPGD P15428 2/20 0.54
KDM4E B2RXH2 1/20 0.54
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
HSD17B10 Q99714 1/20 0.50
ESR1 P03372 1/20 0.50
CYP19A1 P11511 1/20 0.50
ESR2 Q92731 1/20 0.50
CYP3A4 P08684 1/20 0.50
MAPK1 P28482 1/20 0.50
ANO1 Q5XXA6 1/20 0.49
MTNR1A P48039 1/20 0.49
MTNR1B P49286 1/20 0.49
HSP90AB1 P08238 1/20 0.49
EGFR P00533 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30336005 1.00 POLB (0.64) POLBALDH1A1HPGDKDM4ENPC1
SCHEMBL4034916 0.86 MTNR1A (0.56) POLBALDH1A1HPGDKDM4ENPC1
SCHEMBL3296862 0.86 POLB (0.73) POLBALDH1A1HPGDKDM4ENPC1
SCHEMBL8764395 0.86 EGFR (0.57) POLBALDH1A1KDM4EHSP90AB1EGFR
SCHEMBL30619656 0.86 EGFR (0.57) POLBALDH1A1KDM4EHSP90AB1EGFR
SCHEMBL30335932 0.86 POLB (0.73) POLBALDH1A1HPGDKDM4ENPC1
SCHEMBL21437412 0.85 POLB (0.59) POLBALDH1A1HPGDNPC1RAB9A
SCHEMBL29591243 0.85 POLB (0.59) POLBALDH1A1HPGDNPC1RAB9A
SCHEMBL31263830 0.85 KDM4E (0.52) POLBALDH1A1HPGDKDM4EHSD17B10
SCHEMBL1922899 0.85 KDM4E (0.52) POLBALDH1A1HPGDKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115894425-A Fused tricyclic compound, preparation method and application thereof in medicine 江苏恒瑞医药股份有限公司 2023-04-04 CN disclosed
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed
EP-1513817-A1 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY Takeda Pharmaceutical Company Limited (JP) 2005-03-16 EP disclosed
WO-2003099793-A9 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL (JP) 2005-02-10 WO disclosed
WO-2003099793-A1 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 POLB 4532/4885ALDH1A1 1442/4885HPGD 3297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.